Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of “Moderate Buy” from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $48.38.

Several research firms recently commented on TARS. Barclays boosted their price objective on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Jefferies Financial Group raised their price objective on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Oppenheimer reiterated an “outperform” rating and set a $59.00 target price (up from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. HC Wainwright upped their price target on Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, Lifesci Capital restated an “outperform” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, December 26th.

Tarsus Pharmaceuticals Trading Down 1.4 %

NASDAQ:TARS opened at $34.42 on Thursday. The firm has a market capitalization of $1.18 billion, a P/E ratio of -7.42 and a beta of 1.05. The company has a quick ratio of 6.85, a current ratio of 6.93 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average of $33.78 and a 200 day moving average of $24.16. Tarsus Pharmaceuticals has a 52 week low of $12.48 and a 52 week high of $40.40.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $4.63 million. During the same period in the previous year, the firm posted ($0.49) earnings per share. On average, research analysts predict that Tarsus Pharmaceuticals will post -4.55 earnings per share for the current year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 4,436 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $135,741.60. Following the transaction, the general counsel now directly owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Tarsus Pharmaceuticals news, insider Aziz Mottiwala sold 4,766 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $145,839.60. Following the transaction, the insider now owns 54,075 shares of the company’s stock, valued at $1,654,695. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Bryan Wahl sold 4,436 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the transaction, the general counsel now owns 40,951 shares of the company’s stock, valued at $1,253,100.60. The disclosure for this sale can be found here. Insiders have sold 24,496 shares of company stock worth $749,578 in the last 90 days. 11.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TARS. Charles Schwab Investment Management Inc. raised its holdings in Tarsus Pharmaceuticals by 0.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 139,151 shares of the company’s stock valued at $1,749,000 after acquiring an additional 600 shares during the period. Tower Research Capital LLC TRC raised its stake in Tarsus Pharmaceuticals by 22.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock valued at $92,000 after purchasing an additional 824 shares during the period. Rhumbline Advisers lifted its holdings in Tarsus Pharmaceuticals by 3.3% in the 1st quarter. Rhumbline Advisers now owns 28,518 shares of the company’s stock worth $358,000 after purchasing an additional 924 shares in the last quarter. UBS Group AG boosted its stake in Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after purchasing an additional 1,142 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Tarsus Pharmaceuticals by 13.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,351 shares of the company’s stock valued at $167,000 after buying an additional 1,309 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.